Evidence map›Paper›PMID 30679661›Full record

ArticleScientific reports2019

Fibrogenic Gene Expression in Hepatic Stellate Cells Induced by HCV and HIV Replication in a Three Cell Co-Culture Model System.

Abdellah Akil, Mark Endsley, Saravanabalaji Shanmugam, Omar Saldarriaga, Anoma Somasunderam, Heidi Spratt, Heather L Stevenson, Netanya S Utay, Monique Ferguson, MinKyung Yi

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Pathophysiological mechanisms of liver injury in COVID-19.Liver international : official journal of the International Association for the Study of the Liver · 2021
    Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Abdellah AkilDepartment of, Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America.
Mark EndsleyDepartment of, Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America.
Saravanabalaji ShanmugamDepartment of, Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America.
Omar SaldarriagaDepartment of Pathology, University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America.
Anoma SomasunderamDepartment of Internal Medicine, Division of Infectious Diseases, University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America.
Heidi SprattCommunity Health, University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America.
Heather L StevensonDepartment of Pathology, University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America.
Netanya S UtayDepartment of Internal Medicine, Division of Infectious Diseases, University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America.
Monique FergusonDepartment of Internal Medicine, Division of Infectious Diseases, University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America.
MinKyung YiDepartment of, Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America. miyi@utmb.edu.ORCID 0000-0002-5978-2452
The University of Texas Medical Branch at Galveston · USOffice of Multidisciplinary Activities · US

Funding

Mechanisms of HCV AssemblyR01AI110358 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI YI, MINKYUNG · 2015 to 2019
$1.9M
NIAID NIH HHS R01 AI110358
6 · The paper itself

Abstract

Retrospective studies indicate that co-infection of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) accelerates hepatic fibrosis progression. We have developed a co-culture system (MLH) comprising primary macrophages, hepatic stellate cells (HSC, LX-2), and hepatocytes (Huh-7), permissive for active replication of HCV and HIV, and assessed the effect of these viral infections on the phenotypic changes and fibrogenic gene expression in LX-2 cells. We detected distinct morphological changes in LX-2 cells within 24 hr post-infection with HCV, HIV or HCV/HIV in MLH co-cultures, with migration enhancement phenotypes. Human fibrosis microarrays conducted using LX-2 cell RNA derived from MLH co-culture conditions, with or without HCV and HIV infection, revealed novel insights regarding the roles of these viral infections on fibrogenic gene expression in LX-2 cells. We found that HIV mono-infection in MLH co-culture had no impact on fibrogenic gene expression in LX-2 cells. HCV infection of MLH co-culture resulted in upregulation (>1.9x) of five fibrogenic genes including CCL2, IL1A, IL1B, IL13RA2 and MMP1. These genes were upregulated by HCV/HIV co-infection but in a greater magnitude. Conclusion: Our results indicate that HIV-infected macrophages accelerate hepatic fibrosis during HCV/HIV co-infection by amplifying the expression of HCV-dependent fibrogenic genes in HSC.

Indexed as

Virus ReplicationCell MovementCell ShapeCoculture TechniquesGene Expression ProfilingHepacivirusHepatic Stellate CellsHepatitis C, ChronicHepatocytesHIVHIV InfectionsHumansImmunologic FactorsLiver CirrhosisMacrophagesMatrix Metalloproteinase 1Immunologic FactorsMatrix Metalloproteinase 1MMP1 protein, human

Identifiers

PMID30679661
PMCPMC6345841
OpenAlexW2912726449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.